Hormone replacement therapy and plasma homocysteine levels

Obstetrics and Gynecology

Volumn 94, Issue 4, 1999, Pages 485-491

  Van Baal, W Marchien ^a,b   Smolders, Raimond G V ^a,b   Van Der Mooren, Marius J ^a,b   Teerlink, Tom ^a,b   Kenemans, Peter ^a,b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DYDROGESTERONE; ESTRADIOL; HOMOCYSTEINE; PROGESTERONE;

ADULT; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

DYDROGESTERONE; ESTRADIOL; FASTING; FEMALE; HOMOCYSTEINE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PROGESTERONE CONGENERS; PROMEGESTONE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0032870857     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(99)00412-3     Document Type: Article

References (42)

1. Ueland P.M., Refsum H., Brattström L. Plasma homocysteine and cardiovascular disease. Francis R.B. Atherosclerotic cardiovascular disease, hemostasis and endothelial function. 1992;183-236 Marcel Dekker, New York.
2. Stampfer M.J., Malinow M.R., Willett W.C., Newcomer L.M., Upson B., Ullman D., et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 268:1992;877-881.
3. Daly L., Robinson K., Tan K.S., Graham I.M. Hyperhomocysteinaemia A metabolic risk factor for coronary heart disease determined by both genetic and environmental influences . Q J Med. 86:1993;685-689.
4. Robinson K., Mayer E.L., Miller D.P., Green R., van Lente F., Gupta A., et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation. 92:1995;2825-2830.
5. Boushey C.J., Beresford S.A.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 274:1995;1049-1057.
6. Graham I.M., Daly L.E., Refsum H.M., Robinson K., Brattström L.E., Ueland P.M., et al. Plasma homocysteine as a risk factor for vascular disease - The European concerted action project. JAMA. 277:1997;1775-1781.
7. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollste S.E. Plasma homocysteine levels and mortality in patients with coronary disease. N Engl J Med. 337:1997;230-236.
8. Steegers-Theunissen R.P.M., Boers G.H.J., Trijbels F.J.M., Finkelstein J.D., Blom H.J., Thomas C.M.G., et al. Maternal hyperhomocysteinemia A risk factor for neural-tube defects? Metabolism. 43:1994;1475-1480.
9. Wouters M.G.A.J., Boers G.H.J., Blom H.J., Trijbels F.J.M., Thomas C.M.G., Borm G.F., et al. Hyperhomocysteinemia A risk factor in women with unexplained recurrent early pregnancy loss . Fertil Steril. 60:1993;820-825.
10. Goddijn-Wessel T.A., Wouters M.G.A.J., Van der Molen E.F., Spuijbroek M.D., Steegers-Theunissen R.P.M., Blom H.J., et al. Hyperhomocysteinemia A risk factor for placental abruption or infarction . Eur J Obstet Gynecol Reprod Biol. 66:1996;23-29.
11. De Vries J.I., Dekker G.A., Huijgens P.C., Jakobs C., Blomberg B.M., Van Geijn H.P. Hyperhomocysteinemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol. 104:1997;1248-1254.
12. Malinow M.R. Homocyst(e)ine and arterial occlusive diseases. J Intern Med. 236:1994;603-617.
13. Stamler J.S., Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev. 54:1996;1-30.
14. Mudd S.H., Skovby F., Levy H., Pettigrew K.D., Wilcken B., Pyeritz R.E., et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet. 37:1985;1-31.
15. Harmon D.L., Woodside J.V., Yarnell J.W., Mcmaster D., Young I.S., McCrum E.E., et al. The common "thermolabile" variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinemia. Q J Med. 89:1996;571-577.
16. Mason J.B., Miller J.W. The effects of vitamins B12, B6, and folate on blood homocysteine levels. Ann N Y Acad Sci. 669:1992;197-203.
17. Ubbink J.B., Van der Merwe A., Vermaak W.J.H., Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Invest. 71:1993;993-998.
18. Czeizel A.E., Dudas I. Prevention of the first occurence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 327:1992;1832-1835.
19. Brattström L., Israelsson B., Norrving B., Bergqvist D., Thorne J., Hultberg B., et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis. 81:1990;51-60.
20. 6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 279:1998;359-364.
21. Blom H.J., Van der Mooren M.J. Hyperhomocysteinemia A risk factor for cardiovascular disease - Influence of sex hormones on homocysteine metabolism . Gynecol Endocrinol. 10:(Suppl 2):1996;75-79.
22. Boers G.H.J., Smals A.G.H., Trijbels J.M.F., Leermakers A.I., Kloppenborg P.W. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest. 72:1983;1971-1976.
23. Wouters M.G., Moorrees M.T., Van der Mooren M.J., Blom H.J., Boers G.H., Schellekens L.A., et al. Plasma homocysteine and menopausal status. Eur J Clin Invest. 25:1995;801-805.
24. Van der Mooren M.J., Wouters M.G.A.J., Blom H.J., Schellekens L.A., Eskes T.K.A.B., Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest. 24:1994;733-736.
25. Van der Mooren M.J., Demacker P.N.M., Blom H.J., De Rijke Y.B., Rolland R. The effects of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women. Fertil Steril. 67:1997;67-73.
26. Mijatovic V., Kenemans P., Netelenbos J.C., Jacobs C., Popp-Snijders C., Peters-Muller E.R.A., et al. Postmenopausal oral 17β-oestradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril. 69:1998;876-882.
27. Mijatovic V., Kenemans P., Jacobs C., Van Baal W.M., Peters-Muller E.R.A., Van der Mooren M.J. A randomized controlled study of the effects of 17β-oestradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol. 91:1998;432-436.
28. Bush T.L., Barrett-Connor E., Cowan L.D., Crqui M.H., Wallace R.B., Suchindran C.M., et al. Cardiovascular mortality and noncontraceptive use of estrogen in women Results from the Lipid Research Clinics Program follow-up study . Circulation. 75:1987;1102-1109.
29. Grodstein F., Stampfer M.J. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 38:1995;199-210.
30. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease A quantitative assessment of the epidemiologic evidence . Prev Med. 20:1991;47-63.
31. Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willett W.C., Rosner B., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 335:1996;453-461.
32. Fiskerstrand T., Refsum H., Kvalheim G., Ueland P.M. Homocysteine and other thiols in plasma and urine Automated determination and sample stability . Clin Chem. 39:1993;263-271.
33. Thomas C.M.G., Van den Berg R.J., Segers M.F.G., Bartelink M.L., Thien T. Inaccurate measurements of 17β-oestradiol in serum of female volunteers after oral administration of milligram amounts of micronised 17β-oestradiol. Clin Chem. 39:1993;2341-2342.
34. Yudkin P.L., Stratton I.M. How to deal with regression to the mean in intervention studies. Lancet. 347:1996;241-243.
35. Mijatovic V., Netelenbos J.C., Van der Mooren M.J., De Valk-de Roo G., Jakobs C., Kenemans P. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine in healthy postmenopausal women. Fertil Steril. 70:1998;1085-1089.
36. Steegers-Theunissen R.P.M., Boers G.H.J., Steegers E.A.P., Trijbels J.M.F., Thomas C.M.G., Eskes T.K.A.B. Effects of sub-50 oral contraceptives on homocysteine metabolism A preliminary study . Contraception. 45:1992;129-139.
37. Finkelstein J. Methionine metabolism in mammals. Effect of age, diet, and hormones on three enzymes of the pathway in rat tissues. Arch Biochem Biophys. 122:1972;583-590.
38. Van Guldener C., Donker A.J., Jakobs C., Teerlink T., De Meer K., Stehouwer C.D.A. No net renal extraction of homocysteine in fasting humans. Kidney Int. 54:1998;166-169.
39. Blom H.J., Boers G.H.J., Elzen J.P.A.M., Van Roessel J.J.M., Trijbels J.M.F., Tangerman A. Difference between premenopausal women and young men in the transamination pathway of methionine catabolism and the protection against vascular disease. Eur J Clin Invest. 18:1988;633-638.
40. Giltay E.J., Hoogeveen E.K., Elbers J.M., Gooren L.J., Asscheman H., Stehouwer C.D. Effects of sex steroids on plasma total homocysteine levels A study in transsexual males and females . J Clin Endocrinol Metab. 83:1998;550-553.
41. Olszewski A.J., McCully K.S. Homocysteine content of lipoproteins in hypercholesterolemia. Atherosclerosis. 88:1991;61-68.
42. Windler E., Kovanen P.T., Chao Y.S., Brown M.L., Havel R.J., Goldstein J.L. The estradiol stimulated lipoprotein receptor of rat liver. J Biol Chem. 255:1980;1964-1971.